Medicine
Review Cycle Records
European Heart Journal-Cardiovascular Pharmacotherapy
Paper Review Records
All Paper Review Records
6 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
Behnood Bikdeli; Azita H Talasaz; Hooman Bakhshandeh; Mohammad Sadegh Hassanvand; Hessam Kakavand; Sepehr Jamalkhani; Sina Rashedi; Sara Tayyebi; Mohammadreza Babaei; Erfan Kohansal; Hamed Ghoshouni; Yasmin Mohtasham Kia; Mahsa Nikkhoo; Bahram Mohebbi; Maryam Aghakouchakzadeh; Saeed Alipour-Parsa; Armin Elahifar; Ehsan Khalilipur; Razieh Omidvar; Maryam Mehrpooya; Seyed Hashem Sezavar; David Jimenez; Luis Jara Palomares; Saeideh Mazloomzadeh; Naser Hadavand; Mehdi Ansari Dogaheh; Majid Maleki; Feridoun Noohi; Luis Ortega-Paz; Jayant K Raikhelkar; Philippe Gabriel Steg; Renato D Lopes; Raffaele De Caterina; Mehdi H Shishehbor; Loren Laine; Dominick J Angiolillo; Sanjay Rajagopalan; Ajay J Kirtane; Gregory Piazza; Gregory Y H Lip; Roxana Mehran; Harlan M Krumholz; Paul M Ridker; Parham SadeghipourShow moreShow less
1. Division of Cardiology, Heart and Vascular Institute, Mass General Brigham, Brigham and Women’s Hospital, Boston, MA 02115, USA; 2. Thrombosis Research Group, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA; 3. Harvard Medical School, Boston, MA 02115, USA; 4. YNHH/Yale Center for Outcomes Research and Evaluation (CORE), New Haven, CT, USA; 5. Department of Pharmacotherapy and Outcomes Sciences, Virginia Commonwealth University, Richmond, VA 23298, USA; 6. Department of Pharmacy, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY 10032, USA; 7. Vascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Institute, Tehran 1995614331, Iran; 8. Cardiovascular Epidemiology Research Center, Rajaie Cardiovascular Institute, Tehran 1995614331, Iran; 9. Clinical Trial Center, Rajaie Cardiovascular Institute, Tehran 1995614331, Iran; 10. Department of Environmental Health Engineering, School of Public Health, Tehran University of Medical Sciences, Tehran 1417613151, Iran; 11. Center for Air Pollution Research (CAPR), Institute for Environmental Research (IER), Tehran University of Medical Sciences, Tehran 1417613151, Iran; 12. Department of Clinical Pharmacy and Pharmacoeconomics, School of Pharmacy, Iran University of Medical Sciences, Tehran 1114133314, Iran; 13. Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran 1989934148, Iran; 14. Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran 1411713138, Iran; 15. Cardiovascular Research Center, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran 1998734383, Iran; 16. Cardiovascular Intervention Research Center, Rajaie Cardiovascular Institute, Tehran 1995614331, Iran; 17. Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran 1419733141, Iran; 18. Research Center for Prevention of Cardiovascular Diseases, Institute of Endocrinology and Metabolism, Tehran 1411713119, Iran; 19. Respiratory Department, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid 28034, Spain; 20. CIBER Enfermedades Respiratorias (CIBERES), Madrid 07110, Spain; 21. Medicine Department, Universidad de Alcalá, Madrid 28801, Spain; 22. Medical Surgical Unit of Respiratory Diseases, Virgen del Rocio Hospital and Instituto de Biomedicina, Seville 41013, Spain; 23. Drug and Food Control Department, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman 76169-13555, Iran; 24. Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL 32209, USA; 25. Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, NY 10032, USA; 26. French Alliance for Cardiovascular Trials, Paris 75018, France; 27. Université Paris-Cité, Paris 75006, France; 28. INSERM Unité 1148, Paris 75018, France; 29. Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital Bichat, Paris 75018, France; 30. Department of Cardiology, Duke University, Durham, NC 27708, USA; 31. University Cardiology Division, Pisa University Hospital, Pisa 56126, Italy; 32. University Hospitals, Harrington Heart and Vascular Institute, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; 33. Section of Digestive Diseases, Yale School of Medicine, New Haven, CT 06510, USA; 34. VA Connecticut Healthcare System, West Haven, CT 06516, USA; 35. Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L69 7ZX, United Kingdom; 36. Department of Clinical Medicine, Aalborg University, Aalborg 9220, Denmark; 37. Department of Cardiology, Lipidology and Internal Medicine with Intensive Coronary Care Unit, Medical University of Bialystok, Bialystok 15-089, Poland; 38. Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; 39. Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT 06510, USA; 40. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT 06510, USA; 41. Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Boston, MA, USAShow moreShow less
The OCEANIC trial journey: from failure to breakthrough?
Valeria Caso; Hugo ten Cate; Isabelle C van GelderShow moreShow less
1. Neurology-Stroke Unit, Saronno Hospital, ASST-Valle Olona , 21047 Saronno ,; 2. Department of Internal Medicine, Thrombosis Expertise Center, Maastricht University Medical Center (MUMC+) CARIM—Cardiovascular Research Institute Maastricht, Maastricht University, PO Box 616, 6200 MD Maastricht ,; 3. Department of Cardiology, University Medical Center Groningen (UMCG), University of Groningen , 9713 GZ, Groningen ,Show moreShow less
Why cardio-rheumatology?
Anne Grete Semb; Eirik Ikdahl; Anne KerolaShow moreShow less
1. Department of Rheumatology, Division of Research and Innovation, Diakonhjemmet Hospital , Diakonveien 12, 0370 Oslo ,; 2. Department of Internal Medicine, Päijät-Häme Central Hospital, Wellbeing Services County of Päijät-Häme , Keskussairaalankatu 7, 15850 Lahti ,; 3. Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki , Tukholmankatu 8, 00250 Helsinki ,Show moreShow less
Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation
Farheen Malik; Mandar Shah; Yu Chang; Ishmum Chowdhury; Sridhar Mangalesh; Ahmed Ashraf Morgan; Ezerioha Pascal; Vishakha Modak; Nachum Lebovics; Suraj Adhikari; Pei-Lun Lee; Wei-Cheng Chen; Kuan-Yu ChiShow moreShow less
1. Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,; 2. Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital , Tainan 704302 ,; 3. Department of Internal Medicine, Jacobi Medical Center/North Central Bronx, Albert Einstein College of Medicine , Bronx, NY 10467 ,; 4. Department of Orthopedics, Shuang Ho Hospital, Taipei Medical University , New Taipei City 23561 ,Show moreShow less
Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation
Claudio Borghi; Federica Fogacci; Arrigo F G CiceroShow moreShow less
1. Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna , Via Massarenti 9, Bologna 40138 ,; 2. Department of Medical Pharmacology, Medical Faculty, Ataturk University , Erzurum 25240 ,; 3. Cardiovascular Medicine Unit, Heart, Chest and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Via Massarenti 9, Bologna 40138 ,Show moreShow less
Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery: a proof-of-concept study
Mary Rezk; Amar Taha; Andreas Martinsson; Susanne J Nielsen; Tomas Gudbjartsson; Lennart Bergfeldt; Florian E M Herrmann; Emma C Hansson; Anders JeppssonShow moreShow less
1. Department of Cardiothoracic Surgery, Sahlgrenska University Hospital , Gothenburg 413 45 ,; 2. Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg 413 90 ,; 3. Department of Cardiology, Sahlgrenska University Hospital , Gothenburg 413 45 ,; 4. Department of Cardiothoracic Surgery, Landspitali University Hospital , Reykjavik 101 ,; 5. Department of Cardiac Surgery, LMU University Hospital, LMU Munich , Munich 81377 ,; 6. DZHK (German Centre for Cardiovascular Research) partner site Munich Heart Alliance , Munich 80802 ,Show moreShow less
FAQ
How long does European Heart Journal-Cardiovascular Pharmacotherapy take to review a manuscript?
As of 2026-11-19, CrushSCI has 6 complete review records for European Heart Journal-Cardiovascular Pharmacotherapy. The fastest paper went from submission to acceptance in 3 days (Why cardio-rheumatology?, received 2026-06-19, accepted 2026-06-22); the slowest took 159 days. The average is 70.7 days and the median is 67.5 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.